about
Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after deliveryThe mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.Viral sequence analysis of HIV-positive women and their infected children: insight on the timing of infection and on the transmission network.The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV.Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy.Maternal HIV status and infant feeding practices among Ugandan women.Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda.Implementation of a programme for the prevention of mother-to-child transmission of HIV in a Ugandan hospital over five years: challenges, improvements and lessons learned.Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda.HIV-1 coreceptor switch during 2 years of structured treatment interruptions.Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.Effect of broad-spectrum parenteral antibiotics on "colonization resistance" of intestinal microflora of humans.Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi.CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding.Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.Measurement of viral load by the automated Abbott real-time HIV-1 assay using dried blood spots collected and processed in Malawi and Mozambique.Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi.Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women.A theme issue by, for, and about Africa: results from Ugandan programme preventing maternal transmission of HIVWeight changes during and after 6 months of breastfeeding in HIV-infected mothers receiving antiretroviral therapy in Malawi.Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania.Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission.Tumor necrosis factor-alpha, Interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected highly active antiretroviral therapy-treated and untreated pregnant women in Mozambique.A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.Polymerase chain reaction for the identification of Bordetella pertussis and Bordetella parapertussis.Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA.Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy.Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
P50
Q28534751-99F653D3-2F5D-4A9D-8F29-669F5887A138Q30863784-7A2C1699-EEF1-4822-9598-A8653CA17073Q34231589-A9937342-D2F3-4CEC-9F43-C81C13E2908BQ34266269-17A1BB64-D282-4C75-A0E8-860C270FF015Q34523530-241574F6-87A7-43C7-AEAD-95AE0BB4ED13Q38385724-FB4D27C1-5C60-4E53-B20F-FF107701F858Q38394525-D1B4C3D4-9889-45F0-BF06-A740D5925DECQ38410459-1ECE5FEB-7572-493C-B20B-819C53FFE291Q38440519-6CBE6C01-648D-4DEC-B1A3-2329807066F8Q38870622-6E2702B4-F22E-44F7-983E-60E9EFD2D4AAQ38877392-57499A8B-E01F-40AC-8C69-9B0E3BC33749Q38878398-A2F36E51-29A0-41CC-A206-28C06E048ADFQ38881148-1EE1B88C-1CF9-4EAE-A189-4FA7D2E38C70Q38894109-65A7D119-6EF7-4176-BF95-C9C87FEC646BQ39520236-B7F859D9-F0D7-448D-AEB7-1CF39651893BQ39828156-E51A2BAF-823E-4EB5-8226-4F9B9A1E382CQ40251666-0DC7D224-D8E1-4D58-9C32-24E81F22FB6EQ40540194-CCB41515-20EB-45F1-93C9-BD968A5BA47EQ40719420-4E692E90-35E3-4255-B55A-A29C102343D3Q40824339-87E1A213-11F1-4357-8FD4-87474E1D9F50Q40833730-365A5DDA-709E-4BEB-A7DA-EA956E7FD504Q40855575-B49A244C-8ABF-47EE-B1C3-7F372D3FE4E9Q40867191-DB59F461-8DEC-49AE-B4E4-852540A0BB3AQ40894200-9F61F78C-B067-419B-B8A7-1DCC9DC2D438Q40962161-C008552A-BD7D-41E3-A288-D987A4E7B2E2Q41760045-C229F127-8093-4A91-A1AD-4A9E2DF705C8Q41918711-4C764E0E-4400-475A-9AFF-59E7A3D72C58Q41936116-9A3E5871-2308-4B11-B1EE-84E03715A28CQ42548356-F0E96689-03A3-4490-BB96-6E01AEE17D2FQ43049052-DD8D0EEA-06D2-488F-9575-7D3045D806C2Q43067976-E0BD45BB-7320-46C0-A33E-7F479C4427F8Q43482078-FCB5FA27-46C7-4D93-9ADA-C3918D191BDEQ43945660-0A6E5F21-A073-4DCC-9FB7-6B72BC70CEDFQ44490174-09B7A10D-511F-4D8E-BF93-6186BA559976Q44495122-9F7ACB09-95BC-48E3-8AAD-C0B47B0F067FQ44559535-35B9EA50-74E5-4E28-B835-A7C13649696EQ45028534-6E67ABCA-3833-4B14-A4F9-92C1308484FCQ45262691-0E50AE85-C710-4584-BFFC-11C7962E53C2Q45330472-BFAEFA50-4643-4F72-B38D-82D01DEA5715Q45355192-F48C022D-4C83-4CFA-B736-97AEE467969C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marina Giuliano
@ast
Marina Giuliano
@en
Marina Giuliano
@es
Marina Giuliano
@nl
type
label
Marina Giuliano
@ast
Marina Giuliano
@en
Marina Giuliano
@es
Marina Giuliano
@nl
prefLabel
Marina Giuliano
@ast
Marina Giuliano
@en
Marina Giuliano
@es
Marina Giuliano
@nl
P106
P21
P31
P496
0000-0003-2789-7797